A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757
in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Studiedetails
Type carcinoma: | SCLC |
---|---|
Stadium: | n/a |
Mutatie: | n/a |
Lijn: | 2de/3de |
Site: | Erasmus MC |
Contactgegevens: | long.oncologie@erasmusmc.nl |
Website: | https://-/ |
Inclusiecriteria
Male and female subjects (> 18 years of age) with histologically or cytologically confirmed relapsed/refractory SCLC who progressed or recurred following 1 platinum-based regimen and at least 1 other prior line of therapy
Note:
[1] re-treatment with a platinum-based regimen is considered a second line of therapy;
[2] platinum-based regimen followed by checkpoint inhibitor/anti-programmed death ligand 1 [PD-L1] as maintenance therapy is considered 1 line of therapy;
[3] in countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with PD-L1 inhibitor, it is required that subjects to have failed PD-L1 inhibitor as part of their first line systemic treatment or not have access to).
Exclusiecriteria
Meer studies
Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie:
TROPION-LUNG01
2de lijns | stadium IIIb-IV | AGA-positive
TEIPP
Stadium IV | 2de lijns
ORCHARD
EGFR | 2de lijn | stadium IV
MK-7684A
1ste lijn | Stadium IV
Mariposa
2de lijn | EGFR | stadium IIIIB - IV
KRYSTAL
stadium IV | 1ste lijn | KRAS G12C mutatie
ImmunoSABR
stadium IV - 1ste, 2de of 3de lijn
GENMAB
2de lijn - stadium IV
Entrectinib
Stadium IIIB-IV | Eerstelijns | ROS1 mutation
Ensure
Eerstelijn | Fase I
CUP/EAP/DAP/DRUP
Lijst van verschillende programma's
AMGEN 757
2de/3de lijn